Curebase, Inc.

Founded in 2017 and based in San Francisco, Curebase, Inc. provides innovative eClinical software solutions that streamline clinical trials, enhancing data quality and patient engagement through advanced technology. Curebase, Inc. develops a comprehensive platform for clinical trials, enabling efficient data collection and management.

The company was founded in 2017 by Tom Lemberg, who has a background in technology and entrepreneurship. The firm is headquartered in San Francisco, California, and has successfully raised USD 40. 00 mn in its most recent Series B funding round in May 2022, led by Industry Ventures and supported by various other investors. The total amount raised by Curebase to date is USD 40.

00 mn, with a current company valuation of USD 194. 64 mn. Curebase specializes in providing a modern eClinical software platform designed for clinical trials, offering electronic Patient Reported Outcomes (ePRO), electronic Consent (eConsent), scheduling, notifications, and integrated Electronic Data Capture (EDC). Their offerings facilitate faster study launches, enhanced data quality, and improved patient engagement through intuitive form builders and seamless mobile access.

The platform serves research organizations and life sciences teams across North America, Europe, and Asia. Curebase's revenue model primarily revolves around subscription-based services for their eClinical platform. Clients engage in direct B2B transactions, with tailored pricing plans based on study size and complexity, including upfront fees for software deployment and ongoing subscription costs. The core services contributing to revenue include ePRO and eConsent, which support the operational efficiency of clinical trials for clients.

In May 2022, Curebase, Inc. raised USD 40. 00 mn in Series B funding to further enhance its software development and expand clinical trial capabilities. The company plans to introduce new product features aimed at improving user experience and efficiency.

Furthermore, Curebase is targeting geographic expansion into additional markets in Europe and Asia by 2023, leveraging the recent funding to support these initiatives.